![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SIRPB2 |
Gene summary for SIRPB2 |
![]() |
Gene information | Species | Human | Gene symbol | SIRPB2 | Gene ID | 284759 |
Gene name | signal regulatory protein beta 2 | |
Gene Alias | PTPN1L | |
Cytomap | 20p13 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B3KTG0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284759 | SIRPB2 | HCC1 | Human | Liver | HCC | 1.98e-10 | 1.14e+00 | 0.5336 |
284759 | SIRPB2 | HCC2 | Human | Liver | HCC | 8.10e-08 | 8.34e-01 | 0.5341 |
284759 | SIRPB2 | HCC5 | Human | Liver | HCC | 4.61e-10 | 8.65e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SIRPB2 | SNV | Missense_Mutation | c.107G>T | p.Arg36Met | p.R36M | Q5JXA9 | protein_coding | tolerated(0.11) | benign(0.275) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SIRPB2 | SNV | Missense_Mutation | novel | c.902N>G | p.Ala301Gly | p.A301G | Q5JXA9 | protein_coding | deleterious(0) | benign(0.143) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SIRPB2 | SNV | Missense_Mutation | novel | c.626N>A | p.Gly209Asp | p.G209D | Q5JXA9 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SIRPB2 | SNV | Missense_Mutation | rs374055663 | c.422N>T | p.Ser141Leu | p.S141L | Q5JXA9 | protein_coding | tolerated(0.66) | benign(0) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SIRPB2 | SNV | Missense_Mutation | rs371415136 | c.694G>A | p.Val232Ile | p.V232I | Q5JXA9 | protein_coding | tolerated(1) | benign(0.068) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SIRPB2 | SNV | Missense_Mutation | rs763155095 | c.943C>T | p.Arg315Trp | p.R315W | Q5JXA9 | protein_coding | tolerated(0.33) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SIRPB2 | SNV | Missense_Mutation | rs148097564 | c.800N>A | p.Ser267Tyr | p.S267Y | Q5JXA9 | protein_coding | deleterious(0.03) | possibly_damaging(0.453) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SIRPB2 | SNV | Missense_Mutation | rs374055663 | c.422N>T | p.Ser141Leu | p.S141L | Q5JXA9 | protein_coding | tolerated(0.66) | benign(0) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SIRPB2 | SNV | Missense_Mutation | novel | c.823N>C | p.Phe275Leu | p.F275L | Q5JXA9 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
SIRPB2 | SNV | Missense_Mutation | rs748316433 | c.266N>A | p.Arg89His | p.R89H | Q5JXA9 | protein_coding | tolerated(0.89) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |